Clearside Biomedical (Clearside Biomedical) Quick Ratio : 4.42 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Clearside Biomedical Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Clearside Biomedical's quick ratio for the quarter that ended in Dec. 2023 was 4.42.

Clearside Biomedical has a quick ratio of 4.42. It generally indicates good short-term financial strength.

The historical rank and industry rank for Clearside Biomedical's Quick Ratio or its related term are showing as below:

CLSD' s Quick Ratio Range Over the Past 10 Years
Min: 1.82 Med: 4.02 Max: 15.59
Current: 4.42

During the past 11 years, Clearside Biomedical's highest Quick Ratio was 15.59. The lowest was 1.82. And the median was 4.02.

CLSD's Quick Ratio is ranked better than
57.89% of 1553 companies
in the Biotechnology industry
Industry Median: 3.51 vs CLSD: 4.42

Clearside Biomedical Quick Ratio Historical Data

The historical data trend for Clearside Biomedical's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Quick Ratio Chart

Clearside Biomedical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Quick Ratio

Get a 7-Day Free Trial

2.31

1.82

9.08

8.54

4.42

Clearside Biomedical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Quick Ratio	Get a 7-Day Free Trial															8.54	8.54	6.85	5.28	4.42

Competitive Comparison of Clearside Biomedical's Quick Ratio

For the Biotechnology subindustry, Clearside Biomedical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearside Biomedical's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Quick Ratio falls into.

Clearside Biomedical Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Clearside Biomedical's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(30.123	-	0)	/	6.813
	=	4.42

Clearside Biomedical's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(30.123	-	0)	/	6.813
	=	4.42

Clearside Biomedical (NAS:CLSD) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Clearside Biomedical Quick Ratio Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearside Biomedical (Clearside Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (NAS:CLSD) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

CLM:Germany CLM:Germany

Address

900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005

Website

https://www.clearsidebio.com

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Executives

Charles A. Deignan	officer: Chief Financial Officer	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
George M Lasezkay	director	1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101
Bradford T Whitmore	10 percent owner	5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Clay Thorp	director, 10 percent owner	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Thomas Ciulla	officer: Chief Medical Officer	C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005
Benjamin R Yerxa	director	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Jeffrey L Edwards	director	2525 DUPONT DR, IRVINE CA 92612
Daniel H. White	director, officer: President and CEO	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Gerald D. Cagle	director	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Brion S. Raymond	officer: Chief Commercial Officer	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Christy L Shaffer	director	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Hatteras Venture Advisors Iv Sbic, Llc	10 percent owner	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
Hatteras Venture Advisors Iii, Llc	10 percent owner	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701